Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ciclesonide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 known ✓ | P04150 | 11/20 | 1.00 |
| ▸ | PGR | P06401 | 7/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CNR1 | P21554 | 1/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.59 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | IL5 | P05113 | 1/20 | 0.59 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.59 |
| ▸ | AR | P10275 | 1/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.59 |
| ▸ | MMP9 | P14780 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | THPO | P40225 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ciclesonide SCHEMBL15830978 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL1753411 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL3688 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL4782166 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL14493775 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL13575757 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL17439183 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL13014882 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL5700709 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 | |
| Ciclesonide SCHEMBL139353 | 1.00 | NR3C1 (1.00) | NR3C1PGRNR1I2ADORA3CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1670482-B2 | USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES | COVIS PHARMA B V (CH) | 2022-06-29 | — | — | EP | claimed |
| US-20190290661-A1 | USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES | COVIS PHARMA B.V. (CH) | 2019-09-26 | — | — | US | claimed |
| EP-1670482-B1 | USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES | TAKEDA GMBH (DE) | 2013-12-25 | — | — | EP | claimed |
| US-8486923-B2 | Use of the combination of ciclesonide and antihistamines for the treatment of allergic rhinitis | TAKEDA GMBH (DE) | 2013-07-16 | — | — | US | claimed |
| US-20130143849-A1 | USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES | NYCOMED GMBH (DE) | 2013-06-06 | — | — | US | claimed |
| EP-1697398-B1 | AQUEOUS SUSPENSIONS OF CICLESONIDE FOR NEBULISATION | NYCOMED GMBH (DE) | 2012-07-04 | — | — | EP | claimed |
| US-20110092471-A1 | USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | NYCOMED GMBH (DE) | 2011-04-21 | — | — | US | claimed |
| US-7879832-B2 | use of 4-[(4-chlorophenyl)methyl]-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)phthalazinone (azelastine), or a stereoisomer, a pharmaceutically acceptable salt or physiologically functional derivative thereof, and ciclesonide, or a pharmaceutically acceptable salt, epimer of ciclesonide | NYCOMED GMBH (DE) | 2011-02-01 | — | — | US | claimed |
| EP-1545548-B1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | NYCOMED GMBH (DE) | 2010-06-30 | — | — | EP | claimed |
| US-20080027034-A1 | Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof | NYCOMED GMBH (DE) | 2008-01-31 | — | — | US | claimed |
| EP-1796679-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | Altana Pharma AG (DE) | 2007-06-20 | — | — | EP | claimed |
| US-20070134165-A1 | Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient | ALTANA PHARMA AG (DE) | 2007-06-14 | — | — | US | claimed |
| US-20070117783-A1 | Aqueous suspensions of ciclesonide for nebulisation | ALTANA PHARMA AG (DE) | 2007-05-24 | — | — | US | claimed |
| US-20070025923-A1 | Use of ciclesonide for the treatment of respiratory diseases | ALTANA PHARMA AG (DE) | 2007-02-01 | — | — | US | claimed |
| EP-1720577-A2 | CICLESONIDE AND GLYCOPYRRONIUM COMBINATION | Altana Pharma AG (DE) | 2006-11-15 | — | — | EP | claimed |
| WO-2006097458-A1 | NOVEL COMBINATION | NYCOMED GMBH (DE) | 2006-09-21 | — | — | WO | claimed |
| EP-1697398-A2 | AQUEOUS SUSPENSIONS OF CICLESONIDE FOR NEBULISATION | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | claimed |
| WO-2006027377-A1 | CICLESONIDE AND SYK INHIBITOR COMBINATION AND METHODS OF USE THEREOF | ALTANA PHARMA AG (DE) | 2006-03-16 | — | — | WO | claimed |
| WO-2005082413-A2 | CICLESONIDE AND GLYCOPYRRONIUM COMBINATION | ALTANA PHARMA AG (DE) | 2005-09-09 | — | — | WO | claimed |
| WO-2005058935-A2 | AQUEOUS SUSPENSIONS OF CICLESONIDE FOR NEBULISATION | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027034-A1 | Ciclesonide and Syk Inhibitor Combination and Method of Use Thereof | SYK, ZAP70, BTK | NR3C1 59/4885PGR 2046/4885NR1I2 1402/4885 |
| US-20190290661-A1 | USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES | TSLP, NR3C1, SERPINA6 | NR3C1 2/4885PGR 3462/4885NR1I2 900/4885 |
| US-20130143849-A1 | USE OF CICLESONIDE FOR THE TREATMENT OF RESPIRATORY DISEASES | TSLP, NR3C1, SERPINA6 | NR3C1 2/4885PGR 3462/4885NR1I2 900/4885 |
| US-20070117783-A1 | Aqueous suspensions of ciclesonide for nebulisation | IL5, IL17A, CYP17A1 | NR3C1 173/4885PGR 1462/4885NR1I2 1305/4885 |
| US-20070134165-A1 | Use of Ciclesonide for the Treatment of Respiratory Disease in a Smoking Patient | IL5, NR3C1, CYP17A1 | NR3C1 2/4885PGR 1628/4885NR1I2 736/4885 |
| US-20070025923-A1 | Use of ciclesonide for the treatment of respiratory diseases | TSLP, IL5, IL33 | NR3C1 4/4885PGR 2645/4885NR1I2 907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.